C4 Therapeutics and Roche Partner to Develop Novel Degrader-Antibody Conjugates

C4 Therapeutics (CCCC) has announced a strategic expansion of its partnership with Roche (RHHBY) to develop degrader-antibody conjugates (DACs), a novel approach to cancer therapy. This collaboration seeks to pioneer a new class of drugs designed to treat various forms of cancer with higher precision. The partnership aims to merge two cutting-edge modalities: antibody-drug conjugation (ADC) and targeted protein degradation (TPD). By leveraging C4's expertise in TPD and Roche's established capabilities in ADCs, the companies intend to create therapies that can specifically target and degrade disease-causing proteins within cancer cells. The DAC platform is designed to improve the precision of drug delivery, potentially reducing systemic toxicity while increasing the efficacy of the protein degradation process. This represents a technical evolution in how biologics are delivered to target sites, moving beyond traditional inhibition toward complete protein removal. For C4 Therapeutics, the continued backing of a pharmaceutical giant like Roche provides significant validation of its TPD platform. While the specific financial terms of the new agreement were not disclosed, such collaborations typically provide critical infrastructure and funding for smaller biotech firms to advance their research pipelines toward clinical application.